Search Results

You are looking at 21 - 30 of 153 items for :

  • "renal cell carcinoma" x
Clear All
Full access

Thai H. Ho and Eric Jonasch

Hereditary renal cell carcinoma (RCC) has been estimated to account for 5% to 8% of all RCC cases, and extrarenal manifestations may present as early as 3 years of age ( Table 1 ). 1 , 2 RCC is a diverse set of cancers that originate from the

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld and Jue Wang

Hollingsworth JM Miller DC Dunn RL . Surgical management of low-stage renal cell carcinoma: technology does not supersede biology . Urology 2006 ; 67 : 1175 – 1180 . 10 Shuch B Lam JS Belldegrun AS . Open partial nephrectomy for the treatment or

Full access

Frank Xiaoqing Liu, Kirstin Heinrich, Catarina Neves, Ying Zheng and Adam Kasle

Background: Avelumab in combination with axitinib (A+Ax) was approved by the FDA for the first-line (1L) treatment of patients with advanced renal cell carcinoma (RCC). We aimed to evaluate the financial impact of adding A+Ax as a 1L treatment

Full access

Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Somedeb Ball, Fred Hardwicke, Lukman Tijani and Shabnam Rehman

Background: While immune checkpoint inhibitors (ICI) are an important addition to the armamentarium in the fight against advanced renal cell carcinoma (aRCC), ICIs are associated with significant endocrine toxicities. We conducted a meta

Full access

Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Lukman Tijani and Shabnam Rehman

for advanced renal cell carcinoma (aRCC). When used individually, both ICIs and VEGFis have significant mucocutaneous toxicities. We performed a systematic review and meta-analysis of phase 3 randomized controlled trials (RCTs) to determine the

Full access

Miguel Angel Quirch, Nusrat Jahan, Meda Srikala, Fred Hardwicke and Lukman Tijani

In recent randomized clinical trials (RCTs), immune checkpoint inhibitor (ICI) and anti-angiogenic tyrosine kinase inhibitor (VEGFi) combinations have been investigated as front-line therapy in advanced renal cell carcinoma (aRCC). We conducted a

Full access

Jarushka Naidoo

biomarker: key limitations. Abbreviations: IC, immune cells; IO, immuno-oncology; N/A, not applicable; NSCLC, non–small cell lung cancer; RCC, renal cell carcinoma; TC, tumor cells. Adapted from Drake et al, ASCO 2018. Immunogenic Tumor Biomarkers “We've all

Full access

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, M. Dror Michaelson, Lakshminarayanan Nandagopal, John L. Gore, Saby George, Ajjai Alva, Naomi Haas, Michael R. Harrison, Elizabeth R. Plimack, Jeffrey Sosman, Neeraj Agarwal, Sam Bhayani, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Thomas H. Gallagher, Steven L. Hancock, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, Bryan Lewis, Brandon Manley, Brittany McCreery, Andrew McDonald, Amir Mortazavi, Phillip M. Pierorazio, Lee Ponsky, Bruce G. Redman, Bradley Somer, Geoffrey Wile, Mary A. Dwyer, CGC, Lydia J. Hammond and Griselda Zuccarino-Catania

disease. 1 Approximately 85% of kidney tumors are renal cell carcinoma (RCC), and approximately 70% are of clear cell histology. 2 – 4 Histologic diagnosis of RCC is established after surgical removal of renal tumors or after biopsy. For therapy

Full access

Benigno Emmanuel Rodriguez Soto, Lorena López Zepeda, Daniela Vázquez Juarez, Alejandro Noguez Ramos, Alberto Villalobos Prieto, Samuel Rivera Rivera, Guillermo Manuel Olivares Beltrán and Raquel Gerson Cwilich

Full access

Michael P. Porter and Paul H. Lange

( 6 Pt 1 ): 2181 – 2185 ; quiz 2435 . 3 Stephenson AJ Chetner MP Rourke K . Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy . J Urol 2004 ; 172 : 58 – 62 . 4